DMP Stock Overview
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Dermapharm Holding SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €33.55 |
| 52 Week High | €49.16 |
| 52 Week Low | €30.95 |
| Beta | 1.05 |
| 1 Month Change | 4.03% |
| 3 Month Change | -15.15% |
| 1 Year Change | -23.58% |
| 3 Year Change | -51.97% |
| 5 Year Change | 2.76% |
| Change since IPO | 19.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| DMP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 7.5% | 3.4% | 1.8% |
| 1Y | -23.6% | -25.9% | 4.2% |
Return vs Industry: DMP exceeded the German Pharmaceuticals industry which returned -26.4% over the past year.
Return vs Market: DMP underperformed the German Market which returned 2.8% over the past year.
Price Volatility
| DMP volatility | |
|---|---|
| DMP Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DMP has not had significant price volatility in the past 3 months.
Volatility Over Time: DMP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 3,497 | Hans-Georg Feldmeier | ir.dermapharm.de |
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription healthcare products, herbal extracts, and other pharmaceutical products.
Dermapharm Holding SE Fundamentals Summary
| DMP fundamental statistics | |
|---|---|
| Market cap | €1.84b |
| Earnings (TTM) | €62.37m |
| Revenue (TTM) | €1.15b |
29.5x
P/E Ratio1.6x
P/S RatioIs DMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMP income statement (TTM) | |
|---|---|
| Revenue | €1.15b |
| Cost of Revenue | €446.60m |
| Gross Profit | €704.14m |
| Other Expenses | €641.78m |
| Earnings | €62.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | 1.16 |
| Gross Margin | 61.19% |
| Net Profit Margin | 5.42% |
| Debt/Equity Ratio | 194.9% |
How did DMP perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield76%
Payout RatioDoes DMP pay a reliable dividends?
See DMP dividend history and benchmarks| Dermapharm Holding dividend dates | |
|---|---|
| Ex Dividend Date | Jun 06 2024 |
| Dividend Pay Date | Jun 10 2024 |
| Days until Ex dividend | 29 days |
| Days until Dividend pay date | 33 days |
Does DMP pay a reliable dividends?
See DMP dividend history and benchmarks